Related references
Note: Only part of the references are listed.Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults
Sherene Min et al.
AIDS (2011)
Antiviral Activity, Pharmacokinetics, and Safety of BMS-488043, a Novel Oral Small-Molecule HIV-1 Attachment Inhibitor, in HIV-1-Infected Subjects
George J. Hanna et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Entry inhibitors in the treatment of HIV-1 infection
John C. Tilton et al.
ANTIVIRAL RESEARCH (2010)
Novel approaches to inhibiting HIV-1 replication
Catherine S. Adamson et al.
ANTIVIRAL RESEARCH (2010)
Novel targets for anti-retroviral therapy
Sanjay Bhattacharya et al.
JOURNAL OF INFECTION (2009)
HIV-1 entry inhibitors: an overview
Daniel R. Kuritzkes
CURRENT OPINION IN HIV AND AIDS (2009)
Maraviroc for previously treated patients with R5 HIV-1 infection
Roy M. Gulick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals
Martin Markowitz et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America
JP Lalezari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
